"Rumors Are Completely False": Lucid Group Rejects Bankruptcy Reports
The company confirms it has sufficient liquidity well into next year.
Already have an account? Sign in.
The company confirms it has sufficient liquidity well into next year.
The new treatment, given with fulvestrant with or without palbociclib, nearly quadrupled progression-free survival versus standard therapy.
Despite Hochul’s one-year moratorium on large data centers, Needham sees limited impact on TeraWulf. Focus shifts to Kentucky’s $19B Anthropic deal and existing NY capacity.
Spero Therapeutics monetizes its Utebzi royalty stream in a $105M non-dilutive financing deal with Healthcare Royalty, extending cash runway to 2H 2029 while funding SP001 development.